fbpx

Blog

Contact Us

Contact us on 1300 369 772 Monday to Friday, business hours

Share this page

PSA announces Community of Specialty Interest for Hospital Pharmacists

21 January 2025

 

The Pharmaceutical Society of Australia (PSA) announces its Hospital Pharmacy Practice Community of Specialty Interest (CSI), a new forum focussed on strengthening support for pharmacists practising in Australia’s hospitals.

 

The Hospital Pharmacy Practice CSI is dedicated to improving care in hospitals, including embedding pharmacists within healthcare teams, facilitating pharmacist prescribing within collaborative care models and improving pharmacist stewardship of medicine management to improve outcomes of transitions of care.

 

Led by an experienced team of hospital pharmacy leaders, the CSI addresses emerging practice needs through collaboration and knowledge sharing.

 

Hospital pharmacists now have access to a members-only Facebook group where they can connect with the CSI, with a dedicated online webinar to be hosted in early 2025.

 

Leading hospital pharmacist Professor Michael Dooley MPS has been appointed to chair the new CSI.

 

On behalf of the PSA Board, National President Associate Professor Fei Sim FPS welcomed and thanked Professor Michael Dooley for leading this important work.

 

“The establishment of this CSI is a testament to PSA’s ongoing commitment to all pharmacists as the peak body representing pharmacists across all areas of practice”

 

PSA Chief Executive Officer Adjunct Associate Professor Steve Morris emphasised the importance of leadership in evolving areas of pharmacy practice.

 

“PSA has heard members’ feedback and are moving to provide more support for pharmacists practising in hospitals. We’re excited to welcome Professor Dooley as Chair of the Hospital Pharmacists CSI, where he will work with us to develop a package of support tailored to the needs of pharmacists practicing in this setting.

 

“Hospital pharmacists have unique experiences in practice and face evolving unique challenges. PSA is proud to continue strengthening our representation of hospital pharmacists with the extensive experience and expertise of Michael and the CSI leadership group.”

 

Hospital Pharmacy Practice CSI Chair Professor Michael Dooley MPS said: “Every day in Australia there are over 24,000 presentations to emergency departments   30,000 admissions into hospital and 100,000 patients receiving non-admitted care through hospitals. Pharmacists have a crucial role in the care of these patients especially as they transition between settings and services.

 

“I am excited to be part of this great initiative and look forward to working alongside such an experienced team at the PSA to help inform and shape the future for hospital pharmacy practice.”

 

The Hospital Pharmacy Practice CSI is an exclusive community for PSA members. The CSI leadership team are set to host a webinar in early 2025 to formally introduce the CSI and its program of work.

 

Chaired by Professor Michael Dooley, the Hospital Pharmacy Practice CSI is led by:

  • Choi-Ling Batten
  • Professor Ian Coombes
  • Lauren Fraser
  • Hannah Knowles
  • Associate Professor Sue Kirsa
  • Richard Marotti
  • Professor Lisa Nissen
  • Associate Professor Bhavini Patel
  • Prasin Rodrigues

 

For more information and to join the new community, visit www.psa.org.au/communities-of-specialty-interest/hospital-pharmacists-csi/

 

About Hospital Pharmacy Practice CSI Chair Professor Michael Dooley MPS

 

Professor Michael Dooley is an experienced clinical pharmacist and leader. His career has focused in the acute healthcare sector and has spanned special clinical roles in oncology through to senior leadership positions within health services. He has led a wide range of initiatives progressing improvement in medication use and clinical pharmacy practice in Australia including development of profession standards of practice and formal training programs. 

 

Having practised across cardiology and oncology before becoming a senior oncology pharmacist at the Peter MacCallum Cancer Centre and then appointed as Director of Pharmacy He undertook research into medicine use in oncology which became the focus of his PhD, and in 2005 he became the Director of Pharmacy at Alfred Health in Melbourne and the inaugural Chair of Clinical Pharmacy of the Faculty of Pharmacy and Pharmaceutical Sciences of Monash University. In this role he has led the development and implementation of a range of innovative pharmacist led practice models spanning inpatient and ambulatory settings.

 

Professor Dooley contributes to many national and local professional committees and working parties related to improving the delivery of quality health care services. Michael has also worked with many health services within Australia and overseas in implementing services to improve medication use, transition of care and uptake of innovative pharmacy services.

 

Professor Dooley is a former President of the Society of Hospital Pharmacists (SHPA).

​

Media contact:   Georgia Clarke   M: 0480 099 798  E: georgia.clarke@psa.org.au

​

Share this page
Share this page

NAPSA Wildcard Pharmacy Student of the Year 2025 Announced

20 January 2025

 

The Pharmaceutical Society of Australia (PSA) is proud to announce Brielle Geard from the University of Tasmania as the 2025 NAPSA Wildcard Pharmacy Student of the Year, awarded at NAPSA Congress in Brisbane.

 

The Pharmacy Student of the Year (PSOTY) competition showcases the top pharmacy students in Australia, celebrating their exceptional skills, knowledge, and dedication to the pharmacy profession. The Wildcard category provides students who did not win their local competition another opportunity to compete and demonstrate their capabilities on a national stage at PSA25 in August.

 

PSA National President Associate Professor Fei Sim FPS congratulated Brielle Geard on their outstanding achievement.

 

“The PSOTY competition is a valuable platform for pharmacy students to showcase their clinical knowledge, communication skills, and professionalism. Brielle has demonstrated excellence in all these areas, and this award highlights their potential as a future leader in the pharmacy profession,” Associate Professor Sim said.

 

The Wildcard competition involved a rigorous assessment process, with participants judged on their ability to solve complex clinical scenarios while effectively communicating with patients and healthcare teams. Brielle stood out for their exceptional communication skills and knowledge.

 

Ms Geard will now progress to the final round of the PSOTY competition, to be held at PSA25 in Sydney, where they will compete against other state and territory winners for the coveted Pharmacy Student of the Year title.

 

PSA acknowledges and thanks the National Australian Pharmacy Students’ Association (NAPSA) for its ongoing support in the Pharmacy Student of the Year competition, which nurtures and inspires the next generation of pharmacists.

 

Media contact:   Georgia Clarke   M: 0480 099 798  E: georgia.clarke@psa.org.au

Share this page
Share this page

Pill testing will save lives this summer

23 December 2024

 

The Pharmaceutical Society of Australia (PSA) welcomes boosted accessibility of pill testing this summer, with New South Wales joining Victoria and the ACT in offering pill testing services.

 

PSA supports drug checking as a method of harm reduction and broadly supports the availability of drug checking services at events like music festivals and at fixed sites.

 

A 2023 evaluation of ACT drug checking service CanTEST revealed only 53% of substances tested matched the expected drug. For those where an additional drug, a different drug or an inconclusive result was found, one-third reported that they ‘definitely will not’ use the drug.1

 

PSA National President Associate Professor Fei Sim FPS said PSA has long advocated for expanded drug checking services, with harm minimisation being an essential principle of Australia’s National Drug Strategy since 1985.

 

“Having drug checking services available is key to reducing the harm of illicit substances,” Associate Professor Sim said.

 

“Drug checking or pill testing is not about telling consumers ‘this substance is safe’, but about allowing them to make an informed decision about the risks of the substances they have.

 

“Every summer we see young people lose their lives at events around the country because they didn’t know what was in the drugs they were taking.

 

“The evidence is overwhelming – pill testing and drug checking saves lives.

 

“But importantly it is also an opportunity for a health professional to provide tailored support and information on illicit drug use and harm.

 

“PSA supports further expansion of drug testing, further investing in trials and research to support evidence-based, informed decisions about pill testing.”

 

1 Olsen A, Baillie G, Bruno R, McDonald D, Hammoud M, Peacock A (2023). CanTEST Health and Drug Checking Service Program Evaluation: Final Report. Australian National University: Canberra, ACT

 

 

Media contact:   Georgia Clarke   M: 0480 099 798  E: georgia.clarke@psa.org.au

Share this page
Share this page

Consumer voices strengthen PSA’s roadmap to 2030

18 December 2024

 

The Pharmaceutical Society of Australia (PSA) today release the Pharmacists in 2030: Strengthening consumer voices report, an addendum to the Pharmacists in 2030 vision released in August 2024.

 

The report reveals the outcomes of fourteen patient focus groups held as part of the broader Pharmacists in 2030 consultation process.

 

Consumers reaffirmed high levels of trust with pharmacists, and expressed broad support for expanding pharmacists’ scope of practice, including prescribing and participating in multidisciplinary teams.

As part of the report, PSA also makes a series of commitments to ensure patients are better served by Australian pharmacists. PSA commits to:

  • maintaining a consumer network to inform and partner in our work, including in PSA’s policy and advocacy, the development of practice guidelines and other practice support materials;
  • utilising the lived experience of consumers to inform pharmacist education, including at PSA’s National Conference; and
  • remunerating consumers for their involvement in projects and consultation.

 

These commitments further promote person-centred care as part of PSA’s role as leaders of professional pharmacy practice.

 

PSA National President Associate Professor Fei Sim FPS said the Pharmacists in 2030 consumer consultation was a powerful testimony to how health sector policy can be strengthened with the views of patients.

 

“Patients and consumers are at the heart of everything we do as pharmacists, and should have a voice when policies are made for the system that is meant to serve them,” Associate Professor Sim said.

 

“Throughout our Pharmacists in 2030 project PSA listened to both pharmacists and consumer focus groups, and the result is a stronger vision for the future.

 

“In releasing these consumer insights PSA also makes a number of commitments to amplifying consumer voices in all that we do. Consumers will continue to be a key part of the work we undertake, from standards and guidelines, to education and policy work. Partnerships which have been ad hoc now become our business-as-usual.

 

“Working directly with consumers and consumer advocates means the communities we serve have a greater say on how pharmacist care is delivered, improving care for all Australians.”

 

The Pharmacists in 2030: Strengthening consumer voices report is available here.

 

Please note that the consumer testimonials in this report are provided solely for informational and illustrative purposes. Media may use these quotes only when attributing to PSA’s Pharmacists in 2030: Strengthening consumer voices report.

 

Media contact:   Georgia Clarke   M: 0480 099 798  E: georgia.clarke@psa.org.au

 

 

 

 

Share this page
Share this page

PSA and Audirie mark first year of partnership, announcing expansion of AI-powered education simulations in 2025

5 December 2024

The Pharmaceutical Society of Australia (PSA) and Audirie are celebrating the first anniversary of partnership, empowering thousands of learners through immersive AI-powered simulations and enhancing their patient counselling and clinical communication skills.

 

In the first year of partnership, PSA and Audirie have:

  • Empowered thousands of pharmacists, interns, and pharmacy assistants through immersive AI-powered simulations.
  • Enhanced patient counselling and clinical communication skills with cutting-edge technology tailored to the unique needs of pharmacy professionals.
  • Strengthened our shared commitment to excellence in education and improved health outcomes for communities across Australia.

 

PSA is expanding use of AI-powered pharmacist prescriber simulations in 2025, giving more learners access to nation-leading technology.

 

PSA National President Associate Professor Fei Sim FPS expressed her enthusiasm for the ongoing partnership and the upcoming launch of the AI-powered simulations.

 

“Our collaboration with Audirie is boosting the capacity of our education programs to deliver real-world experience for pharmacists, interns and assistants, setting them up to succeed in new roles,” Associate Professor Sim said.

 

“Integrating pharmacist prescriber simulations means learners will be able to practically apply knowledge, counselling and prescribing for an AI-driven patient in real-life clinical scenarios.

 

“PSA is proud to be leading the integration of artificial intelligence in pharmacist education, giving our learners the best and most comprehensive education experience in the Australian market.”

 

Audirie Co-founder and CEO Michael Alexander also highlighted the utilisation of AI as a powerful tool in improving learning outcomes.

 

“Our partnership with PSA has been a transformative journey. Over the past year, we’ve empowered pharmacists, pharmacy assistants and pharmacy interns with cutting-edge AI simulations that enhance their skills and confidence. Together, we are shaping the future of pharmacy education and professional development in Australia.”

 

“The integration of AI into the upcoming PSA Pharmacist Prescriber modules represents the next step in our shared vision to elevate the profession. By combining innovative technology with PSA’s expertise, we are equipping pharmacists with tools to excel in their evolving roles and deliver better patient outcomes.”

 

About Audirie

Audirie is a leading provider of AI-driven communication solutions, committed to transforming the way individuals learn and grow. With a focus on immersive learning experiences, Audirie harnesses the power of artificial intelligence to deliver innovative and effective training programs across various industries.

 

Media contact:   Georgia Clarke   M: 0480 099 798  E: georgia.clarke@psa.org.au

​

The Pharmaceutical Society of Australia is the only national peak body that represents all of Australia’s pharmacists across all practice settings. We want every Australian to have access to the best healthcare, and this must include optimising access to pharmacists’ knowledge and medicines expertise at the forefront of our healthcare system.

Share this page
Share this page

PSA-credentialed pharmacists gain new official post-nominals

2 December 2024

 

The Pharmaceutical Society of Australia (PSA) today announces new professional post-nominals for members who have achieved Medication Management Review (MMR) and Aged Care Onsite Pharmacist (ACOP) credentials through PSA training programs.

 

PSA is committed to elevating professional practice and ensuring pharmacists are recognised for their additional skills and qualifications. The new post nominals enable members to display their advanced practice credentials in a way that validates their expertise and commitment to high-quality patient care.

 

Credentialed pharmacist post-nominals provide visible acknowledgement of the advanced clinical skills and area of specialisation, enabling pharmacists to be readily recognised as key players in multidisciplinary teams.

 

Post-nominals are linked to the members current PSA postnominal MPS or FPS, followed by CredPharm with the appropriate credentials in brackets. For example, a PSA Fellow who has achieved their MMR credential would use post nominals FPS CredPharm (MMR).

 

PSA’s Consultant Pharmacists Community of Speciality Interest Chair Deborah Hawthorne FPS CredPharm (MMR) is excited that members are now able to have their credentials recognised through the addition of post nominals.

 

“Our credentialed pharmacist workforce is a really passionate and skilled group of professionals. It’s critical for them to be able to have their expertise recognised by all members of the care team, Ms Hawthorne said.

 

“It’s also important that they’re easily recognisable to consumers – we’ve done a lot of advocacy work with consumer groups recently and for them to have a way of knowing that their pharmacist is qualified and part of a practice community that drives innovation and career-long learning is essential.

 

“These post nominals will go a long way to driving public trust and confidence in our credentialed pharmacist workforce,” Ms Hawthorne concluded.

 

PSA National President Associate Professor Fei Sim FPS said the recognition of PSA’s credentialed pharmacist members through post nominals is the next logical step in support for credentialed pharmacists.

 

“PSA is the home for credentialed pharmacists, as the only organisation with a track record of consistent support, training and advocacy for credentialed pharmacists across all areas of practice.

 

“We have a long and proud history of advocating for credentialed pharmacists and are focused on how we can continue growing and supporting this workforce.

 

“PSA is committed to supporting credentialed pharmacists in a way unmatched by any other organisation at present. I am proud that PSA continues to be the home for credentialed pharmacists,” Associate Professor Sim said.

​

Media contact:   Georgia Clarke   M: 0480 099 798  E: georgia.clarke@psa.org.au

Share this page
Share this page

Renowned journalist Melissa Doyle to host PSA25

28 November 2024

 

The Pharmaceutical Society of Australia (PSA) has announced today that nationally awarded journalist Melissa Doyle AM will return to emcee its national conference PSA25 for a second year, from 1-3 August 2025.

 

An accomplished and awarded journalist with more than 30 years’ experience, Melissa is one of the best-known and trusted voices and faces in Australian media. Melissa will take to the stage across the conference weekend, also returning to host the member-favourite ‘Carnivale’ Gala Dinner on the evening of 2 August 2025.

 

The emcee announcement comes as super early bird registrations open for the 2025 conference, saving members up to 40% on full conference registration.

 

PSA National President Associate Professor Fei Sim FPS shared the announcement, expressing her excitement to have Ms Doyle join the PSA25 team.

 

“PSA is thrilled to welcome Mel back to our national conference for another year, harnessing her decades of experience as a journalist to give delegates the conference experience of a lifetime,” Associate Professor Sim said.

 

“Mel brings an infectious energy and unmatched professionalism to the conference, getting to the heart of what we do and why we do it, both as pharmacists and as the peak body representing our beloved pharmacy profession. I can’t wait to have her join us again at PSA25.”

 

PSA25 is the premier pharmacy education conference, with more than 1000 attendees from across Australia. The three-day conference will run from 1-3 August 2025, at the International Convention Centre, Sydney.

 

Super early bird registrations are open now at www.psa25.com.au

 

​

Media contact:   Georgia Clarke   M: 0480 099 798  E: georgia.clarke@psa.org.au

Share this page
Share this page

Leading innovation in Quality Use of Medicines as PSA’s impact grows

14 November 2024

 

The Pharmaceutical Society of Australia (PSA) today released its 2024 Impact Report, highlighting the meaningful, real-world impact of its projects across the healthcare sector in 2024. From developing pharmacists’ roles in palliative care and Aboriginal health services to pioneering mental health and loneliness training, PSA is leading the Quality Use of Medicines (QUM) agenda, driving medicine safety and improving access to care for Australians.

 

PSA’s Projects team managed over 40 initiatives in the 2023-24 financial year, partnering with government bodies, Primary Health Networks, and other health stakeholders to address priority health areas. The Impact Report showcases these projects, including:

 

Accessible first aid in a mental health crisis: Upskilling more than 400 pharmacists and pharmacy staff in South Australia to recognise early warning signs of mental ill health, with 97.3% of participants reporting increased confidence in providing initial support.

 

Tackling the loneliness epidemic: A world-first training initiative that addresses loneliness as a health risk, with more than 1,200 pharmacists enrolling in this program in its first three months, giving them tools to tackle social isolation and improve patient outcomes.

 

Pharmacists supporting palliative care: Establishing foundation training pathways for pharmacists to upskill in palliative care, as well as preparing to pilot 6 new models of community palliative care pharmacist roles in 2025/26.

 

The report also highlights the personal impact of these projects, including stories of pharmacists like Natasha, who are on the ground supporting rural patients in end-of-life care, demonstrating the critical role pharmacists can play in improving comfort, access, and safety for patients managing terminal conditions.

 

On the release of PSA’s first Impact Report, PSA National President Associate Professor Fei Sim FPS  expresses gratitude to all involved stakeholders and highlights the importance of engaging with the health sector through project partnerships.

 

“As the government-recognised peak body representing all 39,000 pharmacists across all areas of practice, we are proud to be connecting pharmacists and health sector innovators to improve healthcare for all Australians,” Associate Professor Sim said.

 

“This Impact Report showcases projects that drive the Quality Use of Medicines and medicine safety, that enhance access to care and expand scope of practice through new pharmacy services, from palliative care to upskilling our workforce in Aboriginal and Torres Strait Islander health and mental health care.

 

“These projects equip pharmacists with the knowledge and skills necessary to navigate the evolving healthcare landscape and make meaningful impact in their communities. Each project serves as a vital resource, contributing to the ongoing growth and adaptability of the pharmacy profession.

 

“Projects are fundamental to allow innovative ideas to be trialled, validated and improved, and importantly generate the evidence that is needed to enable widescale implementation and translation into everyday policy and practice.

 

“I’d like to thank all the stakeholders and partners who worked with PSA over the past 12 months, and all the pharmacists who have engaged with training or put their hand up to be part of a practice trial. The success of these programs and the positive impact on patient care is only possible with your support,” Associate Professor Sim concluded.

 

The PSA 2024 Impact Report is available for download on the PSA website here.​

 

 

Media contact:   Georgia Clarke   M: 0480 099 798  E: georgia.clarke@psa.org.au

Share this page
Share this page

Pharmacists ready to immunise against RSV in pregnancy

12 November 2024

 

The Pharmaceutical Society of Australia (PSA) welcomes improved availability of federally funded maternal respiratory syncytial virus (RSV) vaccine, Abrysvo, under the National Immunisation Program (NIP), saving parents over $300 each on private immunisation costs.

 

RSV remains a leading cause of childhood hospitalisation, with around 12,000 infants admitted to hospital with severe RSV every winter. Maternal immunisation significantly reduces the risk of severe RSV disease in children in their first six months.

 

As a vaccine listed on the NIP, funding of the administration of the vaccine by community pharmacists will be covered under the NIP Vaccination in Pharmacy (NIPVIP) Program in participating community pharmacies.

 

However, due to an outdated regulatory approach, many states will need to amend their regulations to permit pharmacists to immunise this cohort against RSV.

 

National President Associate Professor Fei Sim FPS welcomed the addition of RSV vaccines to the NIP, urging governments to update regulations now to permit pharmacist immunisers to administer as soon as vaccines are available.

“PSA welcomes the inclusion of Abrysvo on the NIP as an important protection against hospitalisation or death of infants from severe RSV infection and also congratulate Minister Butler and the federal government for their leadership in limiting preventable disease in children,” Associate Professor Sim said.

 

“Now that the vaccine has been added to the NIP, we must ensure that pregnant people are able to access it, no matter where they live.

 

“We need to move to an approach where all immunisers, including pharmacists, can initiate and administer all vaccines, as recommended by the Unleashing the Potential of the Health Workforce Scope of Practice Review.

 

“I urge all states and territories to expand immunisation authorities to allow Australians to access all vaccines they are recommended from their local pharmacist, including Abrysvo,” Associate Professor Sim concluded.

​

 

​

Media contact:   Georgia Clarke   M: 0480 099 798  E: georgia.clarke@psa.org.au

Share this page
Share this page

PSA Annual Report FY 2023-24 released

7 November 2024

The Pharmaceutical Society of Australia (PSA) has released its 2023/24 Annual Report, marking a significant period of growth for both the organisation and the broader profession.

 

Among PSA’s key achievements is the signing of the first Strategic Agreement on Professional Pharmacist Practice with the Australian Government, acknowledging pharmacists’ critical role in healthcare and providing a framework to further empower their expanding scope of practice.

 

The Agreement recognises PSA’s role as the peak body for all pharmacists across all areas of practice, and further articulates a shared goal between our beloved profession and the Commonwealth government on empowering pharmacists’ role in primary care.

 

With a renewed focus on medicines safety, PSA continued to elevate professional standards, publishing reimagined Professional Practice Standards and the 26th edition of the Australian Pharmaceutical Formulary, APF26. These initiatives, combined with targeted training and practice guidance, have equipped pharmacists across Australia with the tools to meet the rising demands of their expanded roles.

 

Throughout the year, PSA advocated vigorously for state and federal reforms to extend pharmacists’ scope of practice. Achievements include launching new pilot programs in community pharmacy, such as the Queensland Scope of Practice Pilot and various initiatives to enable pharmacists to manage conditions like urinary tract infections, provide vaccinations, and support chronic disease management.

 

Much of the work on Pharmacists in 2030 was undertaken in the 2023-24 financial year, including a series of targeted consultations with members, health sector stakeholders, and consumers. The result was a forward-thinking vision launched at PSA24 by Minister for Health and Aged Care, the Hon. Mark Butler MP in August.

 

Reflecting on the year, PSA National President Associate Professor Fei Sim said she feels enormously proud of what the profession has achieved, with PSA supporting it along the way.

 

“Through a turbulent year, our focus has remained firmly on giving our members the professional resources, practice support and education they need to not only survive, but thrive in an expanding profession,” Associate Professor Sim said.

 

“I encourage all pharmacists to become PSA members – the more pharmacists who are members, the more PSA can do to support the profession with high level advocacy, but also at the grassroots level with professional development, education and practice support.

 

“As we look to the year ahead, there is more work to do. I am excited for the future of the profession and realising the benefits of the foundations laid over the past 12 months.”

 

PSA CEO Adjunct Associate Professor Steve Morris said he remains optimistic about the role PSA plays in the pharmacy sector.

 

“PSA’s success over this year reflects our commitment to advocating for and supporting pharmacists at every stage of their careers,” Morris said.

 

“PSA has achieved strong growth in key metrics, including total membership and increased revenue driven through our projects and partnerships despite a challenging economic environment.

 

“I am proud to lead the organisation through this period of stabilisation, maturation and growth. I would like to take this opportunity to recognise the collective contribution of the whole PSA team around the country during 2023/24 financial year for their work in supporting PSA members. I also wish to thank Fei, the National Board, branch committee members and others who have contributed to the considerable output of PSA.”

 

For more details, the full Annual Report 2023-24 is available here.

 

​

Media contact:   Georgia Clarke   M: 0480 099 798  E: georgia.clarke@psa.org.au

​

Share this page

In the spirit of reconciliation, the Pharmaceutical Society of Australia (PSA) acknowledges the Traditional Custodians of Country throughout Australia and their connections to land, sea and community. We pay our respect to their Elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today. We recognise that Aboriginal and Torres Strait Islander peoples were our first pharmacists.

CONTACT US | TERMS OF USE | PRIVACY

© 2025 Pharmaceutical Society of Australia Ltd. All rights reserved.
NOTICE: Upcoming my.psa.org.au website maintenance on Wednesday May 14th. Learn more...
+